WEKO3
アイテム
{"_buckets": {"deposit": "dfbc058b-d469-4861-b755-3fd13641f338"}, "_deposit": {"created_by": 1, "id": "82180", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "82180"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00082180", "sets": ["1"]}, "author_link": ["1023617", "1023619", "1023615", "1023620", "1023618", "1023621", "1023613", "1023616", "1023614"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2021-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageStart": "256", "bibliographicVolumeNumber": "14", "bibliographic_titles": [{"bibliographic_title": "Pharmaceuticals"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Activating double mutations L858R/T790M in the epidermal growth factor receptor\n(EGFR) region are often observed as the cause of resistance to tyrosine kinase inhibitors (TKIs). Third-generation EGFR-TKIs, such as osimertinib and rociletinib (CO-1686), was developed to target such resistance mutations. The detection of activating L858R/T790M mutations is necessary to select sensitive patients for therapy. Hence, we aimed to develop novel radiobromine-labeled CO-1686 as a\npositron emission tomography (PET) imaging probe for detecting EGFR L858R/T790M mutations. Nonradioactive brominated-CO1686 (BrCO1686) was synthesized by the condensation of N-(3-[{2-chloro-5-(trifluoromethyl)pyrimidin-4-yl}amino]-5-bromophenyl) acrylamide with the corresponding substituted 1-(4-[4-amino-3-methoxyphenyl]piperazine-1-yl)ethan-1-one. The radiobrominated [77Br]BrCO1686 was prepared through bromodestannylation of the corresponding tributylstannylated precursor with [77Br]bromide and N-chlorosuccinimide. Although we aimed to provide a novel PET imaging probe, 77Br was used as an alternative radionuclide for 76Br. We fundamentally evaluated the potency of [77Br]BrCO1686 as a molecular probe for detecting EGFR L858R/T790M using human non-small-cell lung cancer (NSCLC) cell lines: H1975 (EGFR L858R/T790M), H3255 (EGFR L858R), and H441 (wild-type EGFR). The BrCO1686 showed high cytotoxicity toward H1975 (IC50 0.18 0.06 M) comparable to that of CO-1686 (IC50 0.14 0.05 M). In cell uptake experiments, the level of accumulation of [77Br]BrCO1686 in H1975 was significantly higher than those in H3255 and H441 upon 4 h of incubation. The radioactivity of [77Br]BrCO1686 (136.3% dose/mg protein) was significantly reduced to 56.9% dose/mg protein by the pretreatment with an excess CO-1686. These results indicate that the binding site of the radiotracers should be identical to that of CO-1686. The in vivo accumulation of radioactivity of [77Br]BrCO1686 in H1975 tumor (4.51 0.17) was higher than that in H441 tumor (3.71 0.13) 1 h postinjection. Our results suggested that [77Br]BrCO1686 has specificity toward NSCLC cells with double mutations EGFR L858R/T790M compared to those in EGFR L858R and wild-type EGFR. However, the in vivo accumulation of radioactivity in the targeted tumor needs to be optimized by structural modification.", "subitem_description_type": "Abstract"}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3390/ph14030256", "subitem_relation_type_select": "DOI"}}]}, "item_8_relation_17": {"attribute_name": "関連サイト", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.mdpi.com/1424-8247/14/3/256#cite", "subitem_relation_type_select": "URI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1424-8247", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "M, Fawwaz"}], "nameIdentifiers": [{"nameIdentifier": "1023613", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "K, Mishiro"}], "nameIdentifiers": [{"nameIdentifier": "1023614", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ryuichi, Nishii"}], "nameIdentifiers": [{"nameIdentifier": "1023615", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "A, Makino"}], "nameIdentifiers": [{"nameIdentifier": "1023616", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Y, Kiyono"}], "nameIdentifiers": [{"nameIdentifier": "1023617", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "K, Shiba"}], "nameIdentifiers": [{"nameIdentifier": "1023618", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "S, Kinuya"}], "nameIdentifiers": [{"nameIdentifier": "1023619", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "K, Ogawa"}], "nameIdentifiers": [{"nameIdentifier": "1023620", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ryuichi, Nishii", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1023621", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2022-03-28"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "517af860d68a961a4ee86a7cb5d0ca28.pdf", "filesize": [{"value": "747.1 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 747100.0, "url": {"label": "pharmaceuticals-14-00256-v2.pdf", "url": "https://repo.qst.go.jp/record/82180/files/517af860d68a961a4ee86a7cb5d0ca28.pdf"}, "version_id": "2ddc67d7-89fe-44eb-a8ab-23429220da2d"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/82180", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-03-16"}, "publish_date": "2021-03-16", "publish_status": "0", "recid": "82180", "relation": {}, "relation_version_is_last": true, "title": ["A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma"], "weko_shared_id": -1}
A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma
https://repo.qst.go.jp/records/82180
https://repo.qst.go.jp/records/821801b9629f9-7883-4428-843f-a52554b256b4
名前 / ファイル | ライセンス | アクション |
---|---|---|
pharmaceuticals-14-00256-v2.pdf (747.1 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-03-16 | |||||
タイトル | ||||||
タイトル | A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
M, Fawwaz
× M, Fawwaz× K, Mishiro× Ryuichi, Nishii× A, Makino× Y, Kiyono× K, Shiba× S, Kinuya× K, Ogawa× Ryuichi, Nishii |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Activating double mutations L858R/T790M in the epidermal growth factor receptor (EGFR) region are often observed as the cause of resistance to tyrosine kinase inhibitors (TKIs). Third-generation EGFR-TKIs, such as osimertinib and rociletinib (CO-1686), was developed to target such resistance mutations. The detection of activating L858R/T790M mutations is necessary to select sensitive patients for therapy. Hence, we aimed to develop novel radiobromine-labeled CO-1686 as a positron emission tomography (PET) imaging probe for detecting EGFR L858R/T790M mutations. Nonradioactive brominated-CO1686 (BrCO1686) was synthesized by the condensation of N-(3-[{2-chloro-5-(trifluoromethyl)pyrimidin-4-yl}amino]-5-bromophenyl) acrylamide with the corresponding substituted 1-(4-[4-amino-3-methoxyphenyl]piperazine-1-yl)ethan-1-one. The radiobrominated [77Br]BrCO1686 was prepared through bromodestannylation of the corresponding tributylstannylated precursor with [77Br]bromide and N-chlorosuccinimide. Although we aimed to provide a novel PET imaging probe, 77Br was used as an alternative radionuclide for 76Br. We fundamentally evaluated the potency of [77Br]BrCO1686 as a molecular probe for detecting EGFR L858R/T790M using human non-small-cell lung cancer (NSCLC) cell lines: H1975 (EGFR L858R/T790M), H3255 (EGFR L858R), and H441 (wild-type EGFR). The BrCO1686 showed high cytotoxicity toward H1975 (IC50 0.18 0.06 M) comparable to that of CO-1686 (IC50 0.14 0.05 M). In cell uptake experiments, the level of accumulation of [77Br]BrCO1686 in H1975 was significantly higher than those in H3255 and H441 upon 4 h of incubation. The radioactivity of [77Br]BrCO1686 (136.3% dose/mg protein) was significantly reduced to 56.9% dose/mg protein by the pretreatment with an excess CO-1686. These results indicate that the binding site of the radiotracers should be identical to that of CO-1686. The in vivo accumulation of radioactivity of [77Br]BrCO1686 in H1975 tumor (4.51 0.17) was higher than that in H441 tumor (3.71 0.13) 1 h postinjection. Our results suggested that [77Br]BrCO1686 has specificity toward NSCLC cells with double mutations EGFR L858R/T790M compared to those in EGFR L858R and wild-type EGFR. However, the in vivo accumulation of radioactivity in the targeted tumor needs to be optimized by structural modification. |
|||||
書誌情報 |
Pharmaceuticals 巻 14, 号 3, p. 256, 発行日 2021-03 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1424-8247 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3390/ph14030256 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.mdpi.com/1424-8247/14/3/256#cite |